Nature's Sunshine Products Inc (NATR): Cash & Equivalents
$93.89M
As of 2025-12-31
$82.50M
As of 2026-06-30
+16.1%
3-year compound annual growth
+0.4%
5-year compound annual growth
+8.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.89M | +10.9% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $84.70M | +2.8% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $82.37M | +37.2% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $60.03M | -30.3% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $86.18M | -6.4% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $92.07M | +71.7% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $53.63M | +5.9% | 2021-03-10, Balance as of period end |
| 2018-12-31 | $50.64M | +18.0% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $42.91M | +32.9% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $32.28M | -22.1% | 2019-03-08, Balance as of period end |
| 2015-12-31 | $41.42M | -29.4% | 2018-03-16, Balance as of period end |
| 2014-12-31 | $58.70M | -24.0% | 2017-03-14, Balance as of period end |
| 2013-12-31 | $77.25M | -2.5% | 2016-03-14, Balance as of period end |
| 2012-12-31 | $79.24M | +34.4% | 2015-03-13, Balance as of period end |
| 2011-12-31 | $58.97M | +23.9% | 2014-03-17, Balance as of period end |
| 2010-12-31 | $47.60M | +34.0% | 2013-03-07, Balance as of period end |
| 2009-12-31 | $35.54M | n/a | 2012-03-05, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $93.03M | +58.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $570.12M | -16.3% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $679.57M | +51.1% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $296.68M | +33.3% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $71.33M | -53.7% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $550.94M | +80.7% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $93.68M | -30.9% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $68.00M | +4.7% |
Compare NATR, TVTX, BBIO, ZLAB side by side · Screen every company in Pharmaceutical Preparations ↗